Trump, GOP In Congress Could Use “Must-Pass” Bills To Bring Health Changes
(By Julie Rovner for Kaiser Health News) Throughout the campaign, President-Elect Donald Trump’s entire health message consisted of promising to
Read More
Month: November 2016
Big Pharma’s big question: Is Trump friend or foe?
(By Dylan Scott for ST A T) W ASHINGTON — Should President Donald Trump make drug makers relieved? Or anxious?
Read MoreHow Could a New Administration Tackle Affordable Care Act Challenges? Look to Medicare
(By Sabrina Corlette and Jack Hoadley for Health Affairs Blog, November 7, 2016) We’re experiencing another round of bad headlines
Read MoreNovel system to get dying patients an experimental cancer drug raises hopes — and thorny questions
(By Karen Weintraub for ST A T) T he drug was still experimental, but clinical trials suggested it could be
Read MoreCourt Blocks New Nursing Home Rule From Taking Effect
(By Rebecca Hersher for NPR) A federal district court in Mississippi has issued an injunction blocking a new rule that
Read MoreCMS makes offer to clear Medicare appeals backlog: 6 things to know
(By Ayla Ellison for Becker’s Hospital Review) In an effort to help clear the backlog of Medicare appeals, CMS has
Read MoreSupreme Court lets pay-to-delay ruling against pharma stand
(By Ed Silverman for ST A T) C ash is not always king. In a move that should settle a
Read MoreCalifornia’s Drug Price Initiative: Will Voters ‘Send A Signal To Washington’?
(By Pauline Bartolone for California Healthline) This year, Mary O’Connor and her father made voting a family affair. O’Connor’s father
Read MoreThis drug discount program is good for Americans. But pharma wants to gut it
(By Ted Slafsky for ST A T) S ticker shock over the cost of drugs isn’t going away any time
Read MoreReview the Plan’s Copays and Coinsurance
There is more to a plan than simply its premiums; it’s the additional expenses, such as copays, coinsurance and formulary
Read More